Device Mixing in Asthma, a General Practice Research Database Study

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare the absolute and relative effectiveness of asthma management in patients on inhaled corticosteroid (ICS) maintenance therapy as Easi-breathe® (EB) - beclometasone dipropionate (BDP) breath-actuated inhaler (BAI) - and as-needed (prn) reliever medication (short-acting beta2-agonist [SABA] therapy) via either a BAI (i.e. Easi-breathe® [EB] salbutamol) or via a pressurised metered dose inhaler (MDI) (e.g. MDI salbutamol).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Research in Real-Life Ltd
• Collaborators: Teva Branded Pharmaceutical Products R&D, Inc.; Teva Pharmaceutical Industries
• Treatments: Albuterol; Beclomethasone

Criteria

Inclusion Criteria:

• Aged: 4-80 years:

• Paediatric cohort (aged 4-11 years), and

• Adult cohort (aged 12-80 years )

• Evidence of asthma:

• a diagnostic code for asthma, and / or

• ≥2 prescriptions for asthma at different points in time during the prior year and/ or

• ≥2 prescriptions for asthma therapies during the outcome year, including ≥1 ICS prescription (in addition to that received at IPD) - IPDI cohort only

• Be on current asthma therapy (for the IPDA cohort only):

• ≥1 ICS prescription in the prior year, and

• ≥1 other asthma prescription during the baseline year.

• Have at least one year of up-to-standard (UTS) baseline data (prior to the IPD) and at least one year of UTS outcome data (following the IPD).

Exclusion Criteria:

• had a COPD read code at any time; and/or

• received a combination inhaler in addition to a separate ICS inhaler in the baseline year; and/or

• received a long-acting beta2-agonsist (LABA) in addition to a separate ICS inhaler in the baseline year

• received ICS therapy during baseline year via DPI (in IPDA cohort only).